CN101568332A - 抑制血管生成及治疗血管生成相关疾病的方法 - Google Patents

抑制血管生成及治疗血管生成相关疾病的方法 Download PDF

Info

Publication number
CN101568332A
CN101568332A CNA2006800561122A CN200680056112A CN101568332A CN 101568332 A CN101568332 A CN 101568332A CN A2006800561122 A CNA2006800561122 A CN A2006800561122A CN 200680056112 A CN200680056112 A CN 200680056112A CN 101568332 A CN101568332 A CN 101568332A
Authority
CN
China
Prior art keywords
compositions
colchicine
muscoril
nab
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800561122A
Other languages
English (en)
Chinese (zh)
Inventor
N·P·德塞
V·特里优
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience Inc USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Inc USA filed Critical Abraxis Bioscience Inc USA
Publication of CN101568332A publication Critical patent/CN101568332A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2006800561122A 2006-08-31 2006-08-31 抑制血管生成及治疗血管生成相关疾病的方法 Pending CN101568332A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/034365 WO2008027055A1 (en) 2006-08-31 2006-08-31 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases

Publications (1)

Publication Number Publication Date
CN101568332A true CN101568332A (zh) 2009-10-28

Family

ID=37763804

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800561122A Pending CN101568332A (zh) 2006-08-31 2006-08-31 抑制血管生成及治疗血管生成相关疾病的方法

Country Status (9)

Country Link
EP (1) EP2056812A1 (es)
JP (1) JP2010502603A (es)
CN (1) CN101568332A (es)
AU (1) AU2006347740A1 (es)
BR (1) BRPI0622006A2 (es)
CA (1) CA2662140A1 (es)
IL (1) IL197276A0 (es)
MX (1) MX2009002054A (es)
WO (1) WO2008027055A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132927A (zh) * 2014-03-27 2016-11-16 因德纳有限公司 无定形形式的硫代秋水仙碱衍生物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUE048521T2 (hu) 2005-08-31 2020-08-28 Abraxis Bioscience Llc Gyengén vízoldékony gyógyszerészeti és antimikrobális hatóanyagokat tartalmazó keverékek
PT2117520T (pt) 2006-12-14 2018-12-04 Abraxis Bioscience Llc Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane
PT2481409T (pt) 2007-03-07 2018-10-18 Abraxis Bioscience Llc Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
TW201012473A (en) * 2008-09-22 2010-04-01 Tty Biopharm Co Ltd Composition of inhibiting pathological angiogenesis
US20100297243A1 (en) 2009-04-15 2010-11-25 Desai Neil P Prion free nanoparticle compositions and methods of making thereof
WO2011076095A1 (en) * 2009-12-21 2011-06-30 Tty Biopharm Company Limited Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
LT2552438T (lt) 2010-03-26 2016-09-26 Abraxis Bioscience, Llc Hepatoceliulinės karcinomos gydymo būdai
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
LT2552415T (lt) 2010-03-29 2016-12-27 Abraxis Bioscience, Llc Vėžio gydymo būdai
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
US20140228299A1 (en) * 2011-09-20 2014-08-14 National University Corporation Tokyo Medical And Dental University Prophylactic and therapeutic agent for neurological diseases using lipoproteins and prophylactic and therapeutic method for neurological diseases
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CN105228612A (zh) 2013-03-12 2016-01-06 阿布拉科斯生物科学有限公司 治疗肺癌的方法
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
EA202092187A1 (ru) 2015-06-29 2021-08-31 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения эпителиоидно-клеточных опухолей
JP2021528362A (ja) 2018-03-20 2021-10-21 アブラクシス バイオサイエンス， エルエルシー ｍＴＯＲ阻害剤およびアルブミンのナノ粒子の投与を介して中枢神経系障害を処置する方法
CN115003284A (zh) 2019-10-28 2022-09-02 阿布拉科斯生物科学有限公司 白蛋白和雷帕霉素的药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318401B1 (it) * 2000-03-17 2003-08-25 Indena Spa Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.
SI1585548T1 (sl) * 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
PT1585548T (pt) * 2002-12-09 2018-10-17 Abraxis Bioscience Llc Composições e métodos de administração de agentes farmacológicos
US6825236B2 (en) * 2003-04-14 2004-11-30 California Pacific Medical Center Colchicine derivatives
ITMI20040164A1 (it) * 2004-02-03 2004-05-03 Indena Spa Derivati di n.deacetiltiocolchicina loro uso e formulazioni farmaceutiche che li contengono
SI3248600T1 (sl) * 2005-02-18 2020-09-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132927A (zh) * 2014-03-27 2016-11-16 因德纳有限公司 无定形形式的硫代秋水仙碱衍生物

Also Published As

Publication number Publication date
WO2008027055A1 (en) 2008-03-06
JP2010502603A (ja) 2010-01-28
IL197276A0 (en) 2009-12-24
EP2056812A1 (en) 2009-05-13
CA2662140A1 (en) 2008-03-06
AU2006347740A1 (en) 2008-03-06
MX2009002054A (es) 2009-05-01
BRPI0622006A2 (pt) 2011-12-20

Similar Documents

Publication Publication Date Title
CN101568332A (zh) 抑制血管生成及治疗血管生成相关疾病的方法
US20080280987A1 (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
AU2019202037B2 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
ES2686150T3 (es) Nanopartícula que comprende rapamicina y albúmina como agente antineoplásico
CN104530256B (zh) 透明质酸维生素e琥珀酸酯聚合物及其制备和用途
CN108135737A (zh) 用于治疗翼状胬肉的组合物和方法
Jin et al. Injectable corilagin/low molecular weight chitosan/PLGA-PEG-PLGA thermosensitive hydrogels for localized cancer therapy and promoting drug infiltration by modulation of tumor microenvironment
ES2315312T3 (es) Procedimiento y composiciones para el tratamiento de enfermedades del ojo.
KR20220125798A (ko) 표적화된 세포 집단의 직접 주사에 의한 치료를 위한 시스템 및 약학적 조성물
Das et al. The gamut of perspectives, challenges, and recent trends for in situ hydrogels: A smart ophthalmic drug delivery vehicle
CN108602879A (zh) 用于治疗疾病的抗体-药物协同作用技术
Li et al. A novel, liposome-loaded, injectable hydrogel for enhanced treatment of choroidal neovascularization by sub-tenon's injection
JP2019525951A (ja) 眼乾燥症候群および他の外傷を受けた非角化上皮表面を処置する組成物および方法
Zhu et al. Multi-targeting liposomal codelivery of cisplatin and rapamycin inhibits pancreatic cancer growth and metastasis through stromal modulation
WO2021058423A1 (en) Composition with drug micro-nano particles of an anti-cancer agent
WO2017000770A1 (zh) 药物组合物及其制备方法和用途
KR20090057074A (ko) 혈관형성 억제 및 혈관형성 관련 질환 치료 방법
CN106727611A (zh) 用于预防和治疗血管性疾病的化合物及其制剂
US20220409560A1 (en) Pharmaceutical Compositions, Formulations And Methods For The Treatment Of Retinoblastoma
Ashique et al. Overview of processed excipients in ocular drug delivery: Opportunities so far and bottlenecks
Berillo et al. Review of Recent Advances in the Use of Drug Delivery Systems in Ophthalmology
De Clercq Development of paclitaxel-loaded gelatin microspheres with a dual application for the treatment of advanced ovarian cancer: prevention of postsurgical peritoneal adhesions and recurrence of peritoneal carcinomatosis
US20190275001A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
TW200810745A (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
CN116687860A (zh) 顺铂靶向脂质体及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091028